Granocyte

Granocyte is a prescription‑only injectable medication that contains the recombinant human granulocyte colony‑stimulating factor lenograstim. It is supplied as a sterile solution for intravenous or subcutaneous use and is marketed in the European Union. Granocyte belongs to the hematopoietic growth factor class and is intended to support neutrophil production in patients with chemotherapy‑induced neutropenia or post‑transplant neutropenia. The product requires a prescription and should be administered by a healthcare professional.

Granocyte is used to reduce the risk of infection in patients whose neutrophil counts are low due to specific medical treatments.

- Management of chemotherapy‑induced neutropenia in adult cancer patients. - Prevention of febrile neutropenia during high‑dose chemotherapy regimens. - Support of neutrophil recovery after autologous or allogeneic bone marrow transplantation. - Treatment of severe neutropenia when rapid hematopoietic stimulation is required. - Use in patients with congenital neutropenia who have inadequate response to other G‑CSF agents. - Adjunct therapy in clinical trials evaluating novel chemotherapy protocols.

The safety profile of lenograstim reflects its pharmacologic activity on the bone marrow and immune system.

Common: - Bone pain, especially in the lower back or limbs. - Mild fever or chills. - Injection site erythema or discomfort. - Fatigue or weakness. - Nausea.

Serious: - Severe allergic reactions such as anaphylaxis. - Splenic rupture or enlargement. - Acute respiratory distress syndrome. - Capillary leak syndrome. - Unexplained bleeding or bruising.

Healthcare providers should evaluate patient history and clinical status before initiating Granocyte therapy.

- Assess baseline neutrophil count and overall bone‑marrow function. - Use caution in patients with a history of hypersensitivity to recombinant proteins. - Monitor for signs of splenic enlargement during treatment. - Adjust dosing in patients with renal or hepatic impairment as recommended. - Avoid use in patients with active uncontrolled infections unless benefits outweigh risks. - Discontinue if severe adverse reactions occur.

Lenograstim may interact with other medications that affect blood cell production or immune responses.

Avoid: - Concurrent use of chemotherapy agents that cause profound myelosuppression without appropriate timing. - Live vaccines administered during treatment, due to altered immune response.

Use with caution: - Corticosteroids, which may blunt the neutrophil response. - Immunosuppressive biologics such as anti‑TNF agents. - Anticoagulants, as rapid neutrophil changes can affect bleeding risk. - Other colony‑stimulating factors, to prevent overlapping toxicity.